A boardroom overhaul and a record commercial pipeline headlined a busy session for small-cap health and property names, while Crism Therapeutics pointed to FDA recognition and grant funding as proof of concept for its early-stage pipeline. Beximco Pharmaceuticals delivered the sharpest price move of the day, surging on the back of a strong set of full-year numbers driven by export growth.
Physiomics flags record commercial pipeline after boardroom overhaul
Physiomics (AIM: PYC) said it is building its largest-ever commercial pipeline in the wake of the boardroom shake-up that saw former directors dismissed in April. The company expects cost savings from the restructured leadership team to more than offset the one-off expenses associated with the transition. Shares edged down 2.32% to 0.464p, though the operational update struck a notably more optimistic tone on the revenue outlook.
Crism Therapeutics secures FDA Orphan Drug Designation for lead programme
Crism Therapeutics Corporation (AIM: CRTX) reported a full-year loss of £1.9 million for 2025, but the headline financials were overshadowed by a string of post-period milestones. The AIM-listed biotech received FDA Orphan Drug Designation for its lead asset and secured nearly £1 million in non-dilutive grant awards, developments that together set the stage for first patient dosing. Shares traded at 10.0p following the news.
Panther Securities sells Peterborough warehouse at premium to book
Panther Securities (AIM: PNS) completed the disposal of a vacant 50,000 sq ft warehouse in Peterborough for £3.25 million, booking a £250,000 uplift to book value on a property it has held since 2023. The sale trims the company's vacancy exposure while crystallising a modest gain, and the shares rose 1.754% to 290.0p on the announcement.
Beximco Pharma posts 11% revenue rise as export sales surge 38%
Beximco Pharmaceuticals (LSE: BXP) delivered a strong set of full-year results for the year ended 30 June 2025, with revenue up 11% and international sales surging 38% as the Bangladesh-based generic drugmaker continued to expand its export footprint. Profit also moved higher over the period. The results drove the sharpest move of the session in this segment, with shares jumping 17.647% to 50.0p.
